Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lateral Flow Urine Assay Detects TB In HIV+ Adults

By LabMedica International staff writers
Posted on 02 Jun 2016
Tuberculosis (TB) is a leading cause of death in human immunodeficiency virus (HIV)-positive people and conventional sputum tests for TB take time and are not always accurate in people with HIV.

A point-of-care test that does not depend on sputum evaluation, if sufficiently accurate, could help HIV-positive people who suffer high morbidity and mortality, by earlier detection of TB that may be missed by conventional sputum testing.

An international review team led by the those at the Liverpool School of Tropical Medicine (UK) have prepared a systematic review to assess the accuracy of a point-of-care urine test for diagnosing and screening for TB in people living with HIV infection. More...
The review looked at accuracy of the lateral flow urine lipoarabinomannan assay (LF-LAM), a commercially available test that detects lipoarabinomannan (LAM), a component of mycobacterial cell walls, which is present in some people with active TB. The test is simple to carry out, requires no special equipment and provides a result within 25 minutes.

The review team examined all data published up until February 5, 2015 and included 12 studies. Six of the studies evaluated LF-LAM for TB diagnosis, looking at people with HIV and TB symptoms, while the other six evaluated the test for TB screening looking at people with HIV regardless of the presence of TB symptoms. The lateral flow urine lipoarabinomannan assay used in the studies was the Alere Determine TB LAM Ag, (Alere Inc.; Waltham, MA, USA), a commercially available point-of-care test for active pulmonary and extrapulmonary TB.

In HIV-positive people with TB symptoms, LF-LAM shows an average sensitivity and specificity of 45% and 92%. Based on these results, in 1,000 HIV-positive people where 30% (300 people) actually have TB, LF-FAM will identify 135 people with TB and miss the diagnosis in 165 with TB. For the 700 people who do not have TB, the test will correctly identify 644 people as not having TB, but will misclassify 56 as having TB. However, the sensitivity of the test is higher in HIV-positive individuals with low CD4 cell counts who are at risk of life-threatening illnesses. In patients with a CD4 less than 100 cells/µL, LF-LAM sensitivity was 56% versus 26% in patients with a CD4 count of more than 100 cells/µL.

Karen R. Steingart, MD, the senior author of the study said, “LF-LAM, whether used for diagnosis or screening, has low sensitivity to diagnose TB. However, and this is key, in HIV-positive individuals with low CD4 counts who are seriously ill, LF-LAM may help with the diagnosis of TB.” The study was published on May 10, 2016, in the journal Cochrane Database of Systematic Reviews.

Related Links:
Liverpool School of Tropical Medicine
Alere

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Urine Analyzer
respons® UDS100
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.